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Abstract The purpose of this study was to determine
the mechanism of the pharmacodynamic interaction
between docetaxel/paclitaxel and cisplatin. Cisplatin-
induced DNA-adducts and cisplatin accumulation
were quantitated in peripheral blood leukocytes
(WBC). The WBC were obtained from patients treated
with docetaxel or paclitaxel in phase I/II studies and
were incubated in vitro with cisplatin. In addition,
blank whole-blood samples were obtained from pa-
tients and healthy subjects and incubated in vitro with
cisplatin or docetaxel/paclitaxel and cisplatin. The cis-
platin-induced DNA-adduct levels measured in WBC
after treatment with docetaxel or paclitaxel were signif-
icantly lower than those determined in non-pretreated
WBC. Docetaxel and paclitaxel reduced the intracellu-
lar accumulation of cisplatin in WBC by 46—47%. If the
pharmacodynamic interaction between docetaxel/pac-
litaxel and cisplatin also occurs in other normal tissues
such as bone marrow, it may well contribute to the
sequence dependent toxicity that has been observed in
clinical studies.
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Introduction
Docetaxel and paclitaxel are novel antimicrotubule
agents inducing tubulin polymerization and inhibiting
microtubule depolymerization. Clinical studies have
revealed high response rates, particularly in breast and
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ovarian cancer [8, 11]. In vitro, paclitaxel has shown
synergism with cisplatin when given before cisplatin
[3,4], whereas in vivo in humans administration of
cisplatin before paclitaxel has induced more neutro-
penia than has the alternate sequence. This has been
attributed to a reduced clearance of paclitaxel [10].
We have previously reported on a clinical and phar-
macology study in patients with solid tumors, applying
the sequence docetaxel/cisplatin in one group of pa-
tients and that of cisplatin/docetaxel in another group.
It was shown that the levels of cisplatin-DNA adducts
in WBC were markedly lower when docetaxel preceded
cisplatin [13]. Indeed, the DNA adduct level measured
at 1 h after cisplatin infusion (dose of 75 mg/m2) was
0.54$0.4 pg Pt/lg DNA for the sequence
docetaxel/cisplatin and 1.21$0.34 pg Pt/lg DNA for
the reverse sequence (P(0.0001) [13]. In addition,
significantly less granulopenia (P(0.001) and mucosi-
tis (P(0.01) were observed for the sequence
docetaxel/cisplatin than for the reverse sequence. There
was no significant mutual pharmacokinetic interaction
between docetaxel and cisplatin. Here we report on
additional in vitro experiments that contribute to a bet-
ter understanding of the mechanism of interaction.
Materials and methods
Patients were treated either with docetaxel (55—100 mg/m2) and
cisplatin (50—100 mg/m2) in a phase I/II study (n"22) [12] or with
single agent docetaxel (100 mg/m2) (n"6) or paclitaxel (135 mg/m2;
n"3) in phase I/II studies. All patients gave written informed
consent and had a WHO performance status of 41 and adequate
renal and liver function, i.e., a serum creatinine level of (120 lmol/l
(1.4 mg/dl) and a total bilirubin value of (25 lmol/l (1.5 mg/dl), as
well as a WBC of '4.0]109/l and a platelet count of '100]109/l.
For in vitro incubation with cisplatin, heparinized whole-blood
samples (20 ml) were drawn prior to docetaxel or paclitaxel infusion
and at 3 h postinfusion (i.e., prior to cisplatin administration in the
docetaxel/cisplatin group). In the six patients treated with single-
agent docetaxel and in one of the three patients treated with single-
agent paclitaxel, a third sample was drawn at 24 h postinfusion.
Table 1 Cisplatin-induced DNA adducts determined in WBC of patients treated with docetaxel in the sequence docetaxel/cisplatin or with
single-agent docetaxel or paclitaxel. All blood samples were incubated in vitro with cisplatin (10 lg/ml). Blood samples were collected prior
to (time 0) and at 3 h after docetaxel administration from the 22 patients receiving docetaxel/cisplatin and prior to (time 0) and at 3 and 24
h after the infusion of docetaxel and paclitaxel given as single agents
Cisplatin-DNA adducts in WBC
(pg Pt/lg DNA)
n 0 3 h 24 h
Docetaxel#cisplatin 22 12.1$3.7 3.8$1.6** —
Docetaxel, single-agent 6 10.0$2.0 3.7$1.0** 7.7$2.6*
Paclitaxel, single-agent 3 6.8$1.2 2.8$1.1** 6.1!
*P"0.01 as compared with 3 h after infusion; **P(0.0001 as compared with time 0
!Single observation (in this patient the level at 0 hours was 6.6 and at 3 hours 3.4 pg Pt/g DNA)
Fig. 1 Cisplatin-DNA adduct levels determined in vitro in WBC in
blank blood and blood samples obtained after docetaxel or pac-
litaxel administration [I Blood collected prior to (white bar) and at
3 h after docetaxel infusion (black bar) and incubated with cisplatin
in vitro (n"22), II Patients’ blank blood incubated in vitro with
cisplatin alone (white bar)or with docetaxel#cisplatin (black bar;
n"8), III Blood collected prior to (white bar) and at 3 (black bar)
and 24 h (shaded bar) after docetaxel infusion and then incubated
with cisplatin in vitro (n"6), I» Patients’ blank blood incubated in
vitro with cisplatin alone (white bar) or with paclitaxel#cisplatin
(black bar; n"6), » Blood collected prior to (white bar) and at
3 (black bar) and 24 h (shaded bar, n"1) after paclitaxel infusion and
then incubated with cisplatin in vitro (n"3)]
From eight patients, additional blank blood samples were collected,
i.e., prior to any drug treatment. The samples were incubated in vitro
with docetaxel (1 lg/ml), immediately followed by cisplatin
(10 lg/ml), for 2 h at 37°C in a humidified atmosphere of 5% CO
2
in
air. The level of cisplatin-DNA adducts in WBC and the concentra-
tions of total and unbound cisplatin in the incubation tubes were
measured by atomic spectroscopy (AAS) [6, 7, 9].
The intracellular cisplatin concentration in WBC was measured in
blank whole-blood samples obtained from five patients and two
healthy volunteers. Three 10-ml portions were incubated for 2 h with
cisplatin (10 lg/ml). Prior to cisplatin, docetaxel (1 lg/ml) was ad-
ded to one portion; paclitaxel (1 lg/ml), to the second; and the third
served as a control. WBC were collected after the incubation. The
remaining red blood cells were lysed by the addition of 30 ml buffer
[0.83% NH
4
Cl, 0.1% KHCO
3
, 1 mM ethylenediaminetetra- acetic
acid (EDTA)]. The WBC were washed twice with ice-cold phos-
phate-buffered saline and lysed in 1 ml deionized water. The protein
was quantitated by the Lowry method [5]. After evaporation at
70°C, the sample was digested by nitric acid (65%) at 75°C for 2 h.
The platinum (Pt) concentration was measured by AAS. Student’s
paired and unpaired two-sided t-tests were used for data analysis.
Results and discussion
The DNA-adduct levels determined in vitro after treat-
ment of blank blood with cisplatin in the 22 patients
receiving the combination were 12.1$3.7 and 3.8$1.6
pg Pt/lg DNA before and after docetaxel infusion,
respectively (p(0.0001; Fig. 1, Table 1). In the six
patients treated with single-agent docetaxel, DNA-ad-
duct levels measured pretreatment were 10.0$2.0 pg
Pt/lg DNA, those determined at 3 h 3.7$1.0 pg Pt/lg
DNA (P(0.0001 as compared with preinfusion levels)
and those measured at 24 h post infusion were 7.7$2.6
pg Pt/lg DNA (P"0.01 as compared with 3 h post
infusion). In the three patients treated with paclitaxel,
the DNA-adduct level was 6.8$1.2 pg Pt/lg DNA
before treatment and 2.8$1.1 pg Pt/lg DNA at
3 h after the infusion (P(0.0001). In one of these three
patients from whom a blood sample was also collected
at 24 h after the infusion the DNA-adduct level was 6.6
pg Pt/lg DNA before treatment and 3.4 and 6.1 pg
Pt/lg DNA at 3 and 24 h postinfusion, respectively.
These results indicate a reversible interaction. The 4- to
14-h plasma elimination half-lives of docetaxel and
paclitaxel [1, 2, 12] indicate that the concentrations
determined at 24 h after infusion were already substan-
tially reduced, which suggests that the interaction is
reversed at that time.
Incubation of WBC in vitro with docetaxel (n"8) or
paclitaxel (n"6) and cisplatin resulted in the same
magnitude of inhibition of DNA-adduct formation
(Fig. 1). The intracellular concentrations of platinum in
WBC were reduced by 46% (docetaxel) and 47% (pac-
litaxel), respectively, as compared with the control
values (P(0.0001).
If the pharmacodynamic interaction between
docetaxel/paclitaxel and cisplatin also occurs in other
383
normal tissues such as bone marrow, it may well con-
tribute to the sequence-dependent toxicity. This sug-
gests that the drug schedule is an important determi-
nant not only of activity but also of toxicity.
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